Introduction
The prevalence of epilepsy in children with Down syndrome (DS) is estimated to be 1.4% and is considered to be not much higher than in the general population (1) . The electroclinical features of epilepsy in DS patients have been well studied. (2, 3) . Infantile spasms (IS) are the most common seizures observed (4) (5) (6) . In a large series of children with West syndrome (WS), about 1% had DS (7) .
Neuropathological abnormalities are present in the brain of persons with DS (8, 9) , and together with abnormal neuronal excitability they may lead to increased seizure susceptibility (10) .
In 1940 the use of vitamin B6 in epilepsy was reported by Spies (11) . Since then, several reports on B6 treatment in epilepsy have been published (12) (13) (14) . In his recent book on vitamin responsive conditions, Baxter (15) discusses WS and pyridoxine in detail. Since Othahara first attempted to treat WS with high-dose vitamin B6 (16) , it has been recognized as the treatment of choice in WS in Japan. In our previous study in 15 DS patients with WS, two responded well to vitamin B6 (17) .
In this retrospective study, we report seven patients with DS and WS treated with vitamin B6 and discuss the mechanisms of vitamin B6 in WS.
Materials and Methods
Among 20 patients with DS and WS referred to the neuropediatric service of the Hospital Juan P. Garrahan, Buenos Aires, Argentina between February 1990 and December 2002. Thirteen patients were treated conservately with adrenocorticotropic hormone (ACTH) in eight, combined with valproic acid in four of them, vigabatrin in four and vigabatrin plus valproic acid in the remaining one. Seven patients (four girls and three boys) were treated according to the new alternative treatment scheme with vitamine B6. Four of these seven patients had previously received vigabatrin and three ACTH but they did not respond well to the treatment. The antiepileptic drugs (AEDs) were stopped at initiation of B6. All of them had trisomy 21 and they were diagnosed during the first days of life due to dysmorphic features. They had no relevant personal and family history of febrile seizures or epilepsy. No other type of seizure was observed previous to the onset of IS. In all patients except one, a routine interictal electroencephologram (EEG) during sleep was performed before the onset of IS and in all patients an EEG recording was done before the beginning of treatment. Treatment with vitamin B6 for IS was initiated in five patients two weeks, and in two patients four weeks after starting to receive antiepileptic drugs. One of them who initially received pyridoxine 200 mg per day (25 mg/kg/day) intravenously during three days with a partial spasms control, responded well to oral vitamin B6 400 mg per day (40 mg/kg/day) associated with valproic acid 50 mg/kg/day five months later. Response assessment was based on cessation of spasms and disappearance of hypsarrhythmia and paroxysmal activity on interictal sleep EEG recordings and on parental report through a seizure diary. Video-EEG recordings were not registered in any of the patients.
Results
Clinical examination showed no abnormal signs other than the typical features of DS. The cerebral imaging (computerized tomography and magnetic resonance imaging) performed in all patients was also normal. EEGs performed before the onset of IS showed no abnormalities. The mean age at onset of spasms was 6.5 months (range, 3 to 11 months). All patients had symmetrical mixed (four patients) or flexor (three patients) spasms, occurring in clusters. The spasms were not recorded and interictal EEGs showed symmetric hypsarrhythmia in all patients. Pyridoxine treatment was started at a mean age of 9.5 months, ranging from 3 to 14 months. The time between the onset of spasms and vitamin B6 administration ranged from 2 to 4 weeks. The dose of oral pyridoxine was between 200 and 400 mg/day (25-50 mg/kg/day). Cessation of spasms was obtained within 2 weeks of treatment in four patients.
Their EEGs became normal as soon as the spasms disappeared. In the other patient, EEG showed the hypsarrhythmia (Figure 1 ). She initially did not respond to a three-day course of intravenous pyridoxine 200 mg/day (25 mg/kg/day). In spite of West and Down syndromes and pyridoxine R H Caraballo et al receiving different antiepileptic drugs, the IS could not be controlled. Five months later, at 14 months of age, the EEG still showed similar electroclinical features ( Figure 2 ) and she started with oral pyridoxine 400 mg/day (40 mg/kg/day), combined with valproic acid 50 mg/kg/day. The spasms ceased at 15 months of age and EEG was normal at 16 months of age ( Figure  3 ). Two patients did not respond well to either pyridoxine or vigabatrin, ACTH, valproic acid or benzodiazepines.
In four patients whose spasms ceased, pyridoxine was discontinued after 24 and 30 months and clinical spasms did not recur. These four children did not experience any other type of seizure after a mean time of follow-up of 6 years (range 1-10 years) without any type of treatment. The fifth patient continues taking pyridoxine 400 mg/day (40 mg/ kg/day) after 12 months of follow up and has had no spasms since. None of the patients had adverse events during treatment with pyridoxine. The main electroclinical features and follow up of our series are shown in Table 1 .
Discussion
This study demonstrates a good response in 5/7 patients with IS and DS who were treated with piridoxine. This group was compared to 13 patients treated with vigabatrin and ACTH. Seizure response was similar but side effects were greater in the second group. These results are in a published report (17) .
A favorable outcome in patients with DS has been reported, but only in combination with vigabatrin and ACTH (17) (18) (19) (20) (21) , despite the nonresponse to ACTH in the series of Romano et al (22) .
Nabbout et al. (23) reported a good response to a short course of vigabatrin in patients with WS and DS, as four out of five children recovered from spasms. None of the responders experienced recurrence of spasms or any other type of seizures with a follow-up of between two and four years. 
West and Down syndromes and pyridoxine R H Caraballo et al
This short course of vigabatrin might minimize the probable risk of developing visual field constriction. Many authors reported a good response to pyridoxine in patients with IS. The present series, however, is the first to show good response to pyridoxine in patients with both IS and DS (4, 17) .
Most authors found response to occur within a week or so but, duration of the treatment varied. Othsuka et al. (24) reported some response after a median of five days with a maximum of eleven and complete seizure control by a maximum of 16 days. In the present series of patients, cessation of spasms was obtained in four cases; after one week of treatment in two patients and within two weeks in the other two. The control EEG became normal as soon as the spasms disappeared in all four cases. In the fifth patient, spasms and hypsarrhythmia disappeared after one month of pyridoxine treatment combined with valproic acid. This patient received pyridoxine intravenously during three days after onset of IS but did not respond well to the drug.
Other authors used either low or high doses of pyridoxal phosphate or pyridoxine hydrocloride without showing significant difference in efficacy (25) (26) (27) . Further studies would be necessary to elucidate the difference between the two types of vitamin B6 and dosage.
Only one long-term follow-up study has been reported in 25 patients with WS, 8 of whom with cryptogenic and 17 with symptomatic, who were responsive to vitamin B6. Twenty-one (84%) of these patients continued to be seizure-free at the last visit (28) . All cryptogenic and seven symptomatic WS patients had an IQ of 75 or higher. Pyridoxine therapy was discontinued without seizure relapse in four cryptogenic and in four symptomatic patients. EEGs showed no epileptic discharges in any of the responders. Four of our five patients did not have relapses either and the EEG showed no abnormalities after 24 to 30 months after pyridoxine therapy was discontinued.
The precise mechanism of pyridoxine in WS is unknown, but one hypothesis would be the influence of vitamin B6 on gamma aminobutiric acid (GABA), which is the main inhibitory neurotransmitter in the human central nervous system. Studies have shown that GABA levels in cerebrospinal fluid (CSF) in patients with WS are lower than in controls (29, 30) . Furthermore, Kurlemann et al. (30) reported a patient in whom the GABA levels in CSF increased to within normal ranges after high-dose vitamin B6 therapy. The mechanism of pyridoxine in patients with WS and DS is not known either. High-dose vitamin B6 combined with standard agents has also been used in the treatment of WS. Two reports show successful treatment of WS with a combination of pyridoxal phosphate (40-50 mg/kg/day) and low dosages of ACTH and a combination of vitamin B6 and valproic acid (25) (26) (27) (28) (29) (30) (31) . The authors concluded that this last combination is more effective than valproic acid monotherapy in controlling WS.
The reported incidence of side effects associated with high-dose vitamin B6 is relatively high. Side effects include appetite loss, vomiting, diarrhea, constipation, hemorrhagic gastritis, liver dysfunction, marked abdominal flatulence, peripheral polyneuropathy and rhabdomyolisis (25) . The most common side effects are gastrointestinal symptoms. Most of these side effects are mild and resolve after reduction or discontinuation of pyridoxine (25) .
We could not find any factors predicting the response to pyridoxine, such as additional type of exogenous factors, type of chromosome anomalies or family history of seizure disorders.
In conclusion, because of rapid response without side effects within the first 2 weeks, we consider an oral dose of 200-400 mg/day (25-50 mg/kg/day) of pyridoxine as only treatment or in combination with classic AEDs to be an alternative choice of therapy in patients with IS and DS. Furthermore, patients who initially do not respond well to pyridoxine could be treated again and for a longer period. Taking into account the limitations of retrospective research, further studies are necessary to determine the optimal dosing schedule and to identify patients most likely to respond.
